References
1. Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet.
2021;397(10290):2195-211.2. NCFS. Nederlandse CF Registratie Jaarrapport
2022. Baarn, Nederland; 2023.3. EMA. Summary of Product Characteristics
- SYMKEVI.: European Medicines Agency; 2018. Contract No.:
EMEA/H/C/004682 - X/0015/G.4. FDA. CLINICAL PHARMACOLOGY AND
BIOPHARMACEUTICS REVIEW SYMDEKO (TEZACAFTOR/IVACAFTOR). 2017
28-06-2017.5. Walker S, Flume P, McNamara J, Solomon M, Chilvers M,
Chmiel J, et al. A phase 3 study of tezacaftor in combination with
ivacaftor in children aged 6 through 11years with cystic fibrosis. J
Cyst Fibros. 2019;18(5):708-13.6. Chan Kwong AHP, Calvier EAM, Fabre D,
Gattacceca F, Khier S. Prior information for population pharmacokinetic
and pharmacokinetic/pharmacodynamic analysis: overview and guidance with
a focus on the NONMEM PRIOR subroutine. J Pharmacokinet Pharmacodyn.
2020;47(5):431-46.7. Vonk SEM, van der Meer-Vos M, Bos LDJ, Neerincx AH,
Majoor CJ, Maitland-van der Zee AH, et al. A Quantitative Method for the
Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate,
Lumacaftor, and Tezacaftor in Plasma and Sputum Using LC-MS/MS and Its
Clinical Applicability. Ther Drug Monit. 2020.8. Vonk SEM, van der
Meer-Vos M, Kos R, Neerincx AH, Terheggen-Lagro SWJ, Altenburg J, et al.
Dried Blood Spot Method Development and Clinical Validation for the
Analysis of Elexacaftor, Elexacaftor-M23, Tezacaftor, Tezacaftor-M1,
Ivacaftor, Ivacaftor Carboxylate, and Hydroxymethyl Ivacaftor Using
LC-MS/MS. Ther Drug Monit. 2024.9. FDA. CLINICAL PHARMACOLOGY REVIEW
KALYDECO (IVACAFTOR). 2012 27-01-2012.10. Fohner AE, McDonagh EM, Clancy
JP, Whirl Carrillo M, Altman RB, Klein TE. PharmGKB summary: ivacaftor
pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics.
2017;27(1):39-42.11. Rowland M. TTN. Clinical pharmacokinetics and
pharmacodynamics. 4th Edition ed: Lippincott Williams & Wilkins, a
Wolters Kluwer business; 2011.12. Vonk SEM, Altenburg J, Mathot RAA,
Kemper EM, Amsterdam Mucociliary Clearance Disease Research G.
Correlation between trough concentration and AUC for elexacaftor,
tezacaftor and ivacaftor. J Cyst Fibros. 2024.13. Desimone ME, Sherwood
J, Soltman SC, Moran A. Telemedicine in cystic fibrosis. J Clin Transl
Endocrinol. 2021;26:100270.